Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement / Intercell AG announces Q1 results and update on development programs: Adjuvant IC31TM opens attractive new market opportunity in Flu - All development projects on track - Strong foc

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

quaterly report

14.05.2007

IC31TM - Clinical results emphasize broad and commercial use in vaccine development

» Protective profile for IC31TM in Phase I Tuberculosis vaccine trial - strong    T-cell immune responses in humans confirming broad pre-clinical data base » Promising pre-clinical data for the use of IC31TM in next generation Flu    vaccines - first clinical trials planned for 2007 » Next Milestones - start of a Phase I "proof-of-concept" clinical trial for    an IC31TM adjuvanted Flu vaccine and strong focus on a commercial use of    IC31TM and further strategic partnerships

All development projects on track and within expected timelines

» Japanese Encephalitis vaccine - all preparations for expected market launch    in the US early 2008 and late 2008 in Europe are on track    Regulatory clearance to start a pediatric Phase II clinical trial in India    obtained - start of Phase II trial within the next few weeks » Hepatitis C vaccine - Phase II "proof-of-concept" study fully recruited -    first data expected by mid 2007 - forward strategies comprise options for    mono- and/or combination therapies » Pneumococcus vaccine - preparations for start of Phase I clinical trial on    track

Nosocomial (hospital-acquired) infections - Building the leading vaccine franchise

» Staphylococcus aureus vaccine partnered with Merck & Co. - safe and immunogenic in Phase I clinical trials - Phase II expected to start in 2007 » Pseudomonas vaccine - preparations for start of clinical Phase II/III trials    on track » Enterococcus/Klebsiella vaccines - AIP® accelerated to progress into    clinical development

Strong financial position - Net loss further reduced

» EUR 7.1 million net loss for Q1 2007 - down 19.3 percent as compared to Q1    2006 » Increase of aggregate revenues -  EUR 1.5 million in Q1 2007 compared to    EUR 0.3 million in Q1 2006 » EUR 7.4 million R&D expenses in Q1 2007 - up 8.8 percent as compared to Q1     2006 » Strong cash position with EUR 86.3 million in liquid funds at March 31, 2007

@@start.t2@@end of announcement                                                 euro adhoc 14.05.2007 06:57:42
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: